secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001628280-24-045112
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint
---------------------------------------------------------------------

- Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).
- Non-GAAP EPS $0.06 vs $0.05; GAAP loss per share $0.07 vs $0.12.
- Pain Treatments +16.7%, Surgical Solutions +18.5%, Restorative Therapies +1.2% (all YoY).
- Agreed to divest Advanced Rehabilitation Business for up to $45M; close expected late 2024/early 2025; proceeds to reduce debt.
- FY2024 guidance: net sales $562-567M, Adj. EBITDA $104-107M, Non-GAAP EPS $0.40-0.42 (midpoints raised).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024045112/0001628280-24-045112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024045112/bvs-20241105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer